Continuous glucose monitor

Global Blood Glucose Monitoring Market Report 2021-2025 - Market is Expected to Increase at a CAGR of 13.8% - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021
Diabetes, Health, Medical devices, Medicine, Branches of biology, Diabetes, Clinical medicine, Medical monitoring, Continuous glucose monitor, Blood sugar level, Glucose, Blood glucose monitoring, Diabetes management

The "Diabetes Management: Blood Glucose Monitoring Devices Market (2021)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diabetes Management: Blood Glucose Monitoring Devices Market (2021)" report has been added to ResearchAndMarkets.com's offering.
  • The burgeoning global blood glucose monitoring market is expected to increase at a healthy CAGR of 13.8%, from nearly $9.1bn in 2019, $9.8bn in 2020, to an estimated $19.7bn in 2025.
  • The blood glucose monitoring devices market includes: conventional handheld blood glucose meters (BGMs) that require frequent fingersticks, and new, sensor-based continuous glucose monitoring systems (CGMs) typically worn the upper arm or abdomen that conveniently monitor blood glucose 24/7, as well as lucrative supplies and software/accessories.
  • This comprehensive medical market and technology report provides:
    In-depth market and competitive analyses (market drivers/limiters, 6-year market forecasts by segment and region, 2019 and 2020 global/regional market share)

Ascensia Diabetes Care Launches Patient Assistance Program To Provide Broader Access To Eversense Continuous Glucose Monitoring System

Retrieved on: 
Tuesday, July 20, 2021
Medicine, Diabetes, Clinical medicine, Medical equipment, Medical monitoring, Continuous glucose monitor, Blood glucose monitoring, Diabetes management, Type 1 diabetes, Minimed Paradigm, Ambulatory glucose profile

PARSIPPANY, N.J., July 20, 2021 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes company, announced it has introduced a Patient Assistance Program in the United States to reduce out-of-pocket costs associated with the Eversense Continuous Glucose Monitoring (CGM) System.

Key Points: 
  • PARSIPPANY, N.J., July 20, 2021 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes company, announced it has introduced a Patient Assistance Program in the United States to reduce out-of-pocket costs associated with the Eversense Continuous Glucose Monitoring (CGM) System.
  • Overall, the Program has the potential to save eligible Eversense users up to $1,200 per year on their cumulative 90-day sensor out-of-pocket costs.
  • Our goal is to make Eversense more affordable and provide improved access to this unique and innovative diabetes management technology."
  • Slattery D, Choudhary P. Clinical Use of Continuous Glucose Monitoring in Adults with Type 1 Diabetes.

FDA Clears Dexcom Real-Time APIs for Third-Party Apps and Devices

Retrieved on: 
Thursday, July 15, 2021
Technology, Mobile, Wireless, Medical devices, FDA, Diabetes, Software, Biotechnology, Internet, Health, Dexcom, Medical technology, Health, Medicine, Web API, API, Diabetes, Continuous glucose monitor

FDA clearance of our real-time APIs further solidifies Dexcom as the leader in interoperable CGM, giving Dexcom users even more choice in how they view and interact with their glucose data, said Jake Leach, chief technology officer at Dexcom.

Key Points: 
  • FDA clearance of our real-time APIs further solidifies Dexcom as the leader in interoperable CGM, giving Dexcom users even more choice in how they view and interact with their glucose data, said Jake Leach, chief technology officer at Dexcom.
  • The new APIs will help seamlessly integrate the power of real-time Dexcom CGM data into some of the leading diabetes and digital health solutions.
  • People with diabetes and their healthcare providers will benefit from the integration of real-time Dexcom CGM data into third-party apps and devices in a multitude of ways.
  • For example, it will:
    For more information about the Dexcom real-time APIs and other offerings for third-party developers, visit Dexcom.com/WebAPI .

Continuous Glucose Monitors (CGM) Medical Device Pipeline Products Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 14, 2021
Diabetes, Health, Medical devices, Medicine, Clinical medicine, Medical specialties, Diabetes, Blood tests, Medical monitoring, Blood glucose monitoring, Continuous glucose monitor, Monitoring, Blood sugar level, Glucose, Medical device

The "Continuous Glucose Monitors - Medical Devices Pipeline Product Landscape, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Continuous Glucose Monitors - Medical Devices Pipeline Product Landscape, 2021" report has been added to ResearchAndMarkets.com's offering.
  • "Continuous Glucose Monitors - Medical Devices Pipeline Product Landscape, 2021" provides comprehensive information about the Continuous Glucose Monitors pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
  • Continuous glucose monitoring system is used for the continuous measurement of blood glucose.
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

Centurion Health Announces Pilot Program Using Innovative Glucose Monitoring Technology For Incarcerated Patients With Diabetes

Retrieved on: 
Wednesday, July 14, 2021
Medicine, Medical monitoring, Clinical medicine, Continuous glucose monitor, Health, Blood glucose monitoring, CGM, Glucose

VIENNA, Va., July, 14, 2021 /PRNewswire/ -- Centurion Health announced today that it has partnered with the Minnesota Department of Corrections (DOC) to introduce a pilot program at Shakopee Correctional Facility using a wearable continuous glucose monitoring (CGM) device.

Key Points: 
  • VIENNA, Va., July, 14, 2021 /PRNewswire/ -- Centurion Health announced today that it has partnered with the Minnesota Department of Corrections (DOC) to introduce a pilot program at Shakopee Correctional Facility using a wearable continuous glucose monitoring (CGM) device.
  • Centurion and the DOC are the first in the country to embrace continuous glucose monitoring for incarcerated individuals with diabetes.
  • Centurion is a leading national provider of healthcare and behavioral health services to incarcerated populations and judicially-involved individuals.
  • Centurion is committed to improving the health of its patients and communities through compassionate care and innovative health solutions.

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Retrieved on: 
Friday, July 2, 2021
Diabetes, Health, Medical devices, Medicine, Medical monitoring, Continuous glucose monitor, Blood glucose monitoring, CGM, New York Stock Exchange, Clinical medicine, Diabetes, Eversense, Senseonics, EVERSENSE, SENSEONICS

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the Plan) in accordance with NYSE American Company Guide Section 711(a).

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the Plan) in accordance with NYSE American Company Guide Section 711(a).
  • On July 1, 2021, Senseonics Compensation Committee granted 5 new non-executive employees non-qualified stock options to purchase an aggregate of 66,000 shares of the Companys common stock as an inducement for such employees to join the Company.
  • Senseonics continues to work to bring its Eversense CGM System to more people with diabetes in the U.S. and other markets around the globe and drives to develop enhancements to the system.
  • Senseonics' CGM systems, Eversense and Eversense XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor.

Senseonics Announces Presentation of PROMISE Data at the American Diabetes Association 81st Scientific Sessions

Retrieved on: 
Monday, June 28, 2021
Research, Mobile, Wireless, Technology, Medical devices, Diabetes, Clinical trials, Software, Hardware, Health, Science, Diabetes, Medicine, Medical equipment, Medical technology, Medical monitoring, Continuous glucose monitor, Blood glucose monitoring, Diabetes management, Blood tests, CGM, Blood sugar level, Minimed Paradigm, Eversense, Senseonics, EVERSENSE, SENSEONICS

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced further presentation of PROMISE Study data evaluating the next generation Eversense CGM System at the American Diabetes Association Virtual 81st Annual Scientific Sessions.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced further presentation of PROMISE Study data evaluating the next generation Eversense CGM System at the American Diabetes Association Virtual 81st Annual Scientific Sessions.
  • The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions in the US.
  • The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more.
  • The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Late-Breaking Data Demonstrate Abbott's FreeStyle® Libre System Supports Health Equity for Millions of Americans Living with Diabetes

Retrieved on: 
Friday, June 25, 2021
Medicine, Diabetes, Clinical medicine, Health, Blood glucose monitoring, Glycated hemoglobin, Dexcom, Type 2 diabetes, Continuous glucose monitor, Diabetes management

Presented at the American Diabetes Association (ADA) 81st Scientific Sessions, the data demonstrate meaningful outcomes for people with diabetes using FreeStyle Libre system, including reductions in HbA1C levels, acute diabetes events and all-cause hospitalizations1,2.

Key Points: 
  • Presented at the American Diabetes Association (ADA) 81st Scientific Sessions, the data demonstrate meaningful outcomes for people with diabetes using FreeStyle Libre system, including reductions in HbA1C levels, acute diabetes events and all-cause hospitalizations1,2.
  • "Abbott is helping to close the health disparity gap for the millions of people living with diabetes.
  • This often-overlooked population is twice as likely to be living with diabetes and CGM access is limited by many state Medicaid programs.
  • A Comparison of Continues Glucose Monitors in Reducing A1c in Type 1 and Type 2 Diabetes: FreeStyle Libre and Dexcom
    2 Hirsch et al.

Dexcom CGM Plays Starring Role at 81st Scientific Sessions of the American Diabetes Association

Retrieved on: 
Friday, June 25, 2021
Diabetes, Health, Medical devices, Medicine, Medical technology, Clinical medicine, Diabetes, Medical monitoring, Dexcom, Blood tests, Continuous glucose monitor, Blood glucose monitoring, Glycated hemoglobin, CGM, Ambulatory glucose profile

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today featured research and data presentations that will headline the 81st Scientific Sessions of the American Diabetes Association (ADA) virtual conference held June 25-29, 2021.

Key Points: 
  • DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today featured research and data presentations that will headline the 81st Scientific Sessions of the American Diabetes Association (ADA) virtual conference held June 25-29, 2021.
  • Poster 77-LB, A Retrospective Analysis of the Association between HbA1c and Continuous Glucose Monitor Use for U.S.
  • For more information about the 81st Scientific Sessions of the American Diabetes Association and to register to virtually attend the conference, visit professional.diabetes.org/scientific-sessions .
  • DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients.

Supersapiens Powered by Abbott’s Libre Sense Glucose Sport Biosensor Announces Garmin Integration

Retrieved on: 
Tuesday, June 22, 2021
Medicine, Diabetes, Medical technology, Medical monitoring, Clinical medicine, Continuous glucose monitor, Blood tests, Blood glucose monitoring, Biosensor, Blood sugar level, CGM, Libre

Atlanta, GA, USA, June 22, 2021 (GLOBE NEWSWIRE) -- Supersapiens, powered by Abbotts Libre Sense Glucose Sport Biosensor, is announcing its initial integration of the Supersapiens Connect IQ app with Garmin.

Key Points: 
  • Atlanta, GA, USA, June 22, 2021 (GLOBE NEWSWIRE) -- Supersapiens, powered by Abbotts Libre Sense Glucose Sport Biosensor, is announcing its initial integration of the Supersapiens Connect IQ app with Garmin.
  • A partnership with global healthcare leader Abbott makes Supersapiens the only energy management ecosystem that directly integrates with a Bluetooth-enabled sports continuous glucose monitor (CGM) the Abbott Libre Sense Glucose Sport Biosensor.
  • We brought the Supersapiens app, powered by Abbotts Libre Sense, to market six months ago with the goal of providing athletes with live visibility of their glucose levels during exercise.
  • The Abbott Libre Sense Glucose Sport Biosensor is intended for athletes to measure glucose.